BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved ...

Alzheimer's disease is the world's most common neurodegenerative disease, affecting more than 50 million people globally. Alzheimer's disease is also among the most fatal, landing as one of the top ...

Forest Laboratories announced that it has submitted a New Drug Application (NDA) for a fixed-dose combination (FDC) of memantine HCl extended release (ER), a receptor antagonist and donepezil HCl, ...

Combining memantine with an older, widely used AD drug further improves measures of cognition, global well-being, activities of daily living, and behavior in people with moderate to severe AD, ...

In the Treatment of Alzheimer’s Disease, Polypharmacy Increases Across Lines of Therapy, According to New Analysis from Decision Resources BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one ...

Hundreds of thousands more dementia patients could be helped by two drugs that temporarily halt its symptoms, according to researchers. In a trial, the treatments, which cost as little as 50p a day, ...

The Department of Health has asked the National Institute for Health and Clinical Excellence (NICE) to produce guidance on using donepezil, galantamine, rivastigmine and memantine in the NHS in ...